Aethlon Medical Reports 85-100 Percent Removal of HIV from Human Blood and Expands HIV-AIDS Treatment Pipeline.

Business Editors & Health/Medical Writers

BIOWIRE2K

LA JOLLA, Calif.--(BW HealthWire)--Sept. 10, 2001

Aethlon Medical (OTCBB:AEMD) announced today that pre-clinical human blood trials of the company's HIV-Hemopurifier(TM) have consistently documented a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one overnight treatment.

"This is a major milestone. Our device is actually performing better than originally expected," said Richard Tullis, Ph.D., chief science officer at Aethlon. "We are now one step closer in our efforts to initiate human trials and deliver this important technology to the market."

The company also announced that it has increased the depth of its HIV/AIDS treatment pipeline to include two proprietary HIV-Hemopurifier(TM) treatments: AEMD-45, which is an immobilized antibody treatment cartridge, and AEMD-61, a treatment cartridge that immobilizes both antibodies for HIV and antisense DNA. Current reported human blood data is for AEMD-45. The company has yet to publish human blood performance data for AEMD-61.

"The results of our human blood studies help to reinforce the potential of AEMD-45 as an important treatment for the growing population of HIV infected who desperately need new therapeutic options," said James A. Joyce, chairman and CEO. "It is also significant that we have expanded the use of our Hemopurfier platform technology to include two HIV-AIDS treatments."

The basis of each HIV-Hemopurifier(TM) is the modification of a widely used hollow-fiber hemodialysis cartridges. In the case of AEMD-45, each cartridge contains immobilized antibodies that effectively bind and remove HIV and toxic viral surface proteins from the blood of infected patients. The treatment technology is designed be an important adjunctive therapy to enhance currently available therapeutic regimes as well as a stand-alone treatment for HIV patients who cannot tolerate the drugs or who have become resistant to the available treatments.

Aethlon Medical is a development stage company that is expanding the applications of a novel, global therapeutic approach for treating HIV/AIDS and other epidemic diseases. The company's platform technology, known as the Hemopurifier(TM), is designed to rapidly reduce the presence of viruses and other intoxicants in the blood. The near term business strategy is to develop new therapies and standards of care for infectious diseases in two major revenue sectors, HIV/AIDS and Hepatitis-C (HCV). Aethlon Medical's lead product candidates, AEMD-45 and AEMD-61, are positioned to fill the urgent need for new HIV/AIDS treatments that are effective in reducing viral load, have fewer side effects, decrease treatment resistance, and protect immune functions. Pre-clinical trials of AEMD-45 consistently document a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one overnight treatment. For more information on Aethlon Medical Inc., visit the company's Web site at www.AethlonMedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. (the "company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers of this press release may obtain additional information on the company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, DC 20549 or by calling the Commission at 800/SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's Web site located at http://www.sec.gov.